13,794
Total Claims
$1.4M
Drug Cost
1,038
Beneficiaries
$1,364
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
-11%
Cost per patient vs peers
$1,364 vs $1,524 avg
-2%
Brand preference vs peers
13.4% vs 13.7% avg
Brand vs Generic
87% generic
Brand: 1,843 claims · $1.2M
Generic: 11,951 claims · $209K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 684 | $517K |
| Sacubitril/Valsartan | 249 | $185K |
| Rivaroxaban | 154 | $154K |
| Empagliflozin | 183 | $144K |
| Evolocumab | 134 | $94K |
| Dapagliflozin Propanediol | 57 | $42K |
| Alirocumab | 55 | $34K |
| Ranolazine | 193 | $22K |
| Ticagrelor | 28 | $18K |
| Metoprolol Succinate | 1,218 | $16K |
| Varenicline Tartrate | 33 | $11K |
| Atorvastatin Calcium | 931 | $10K |
| Flecainide Acetate | 162 | $8,258 |
| Isosorbide Mononitrate | 569 | $7,971 |
| Rosuvastatin Calcium | 368 | $6,575 |
Prescribing Profile
77
Unique Drugs
$1.0M
Patient Profile
71
Avg Age
57%
Female
1.68
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About